Evidence map›Paper›PMID 27853960›Full record

Trial reportJournal of neuro-oncology2017

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Jayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, Yangming Ou, Kyrre E Emblem, Alona Muzikansky, Xuezhu Cai, Linda Douw, John G Evans, Jorg Dietrich and 8 more

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 6 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 6 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma.Apoptosis : an international journal on programmed cell death · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Jayashree Kalpathy-CramerMartinos Center for Biomedical Imaging, Charlestown, USA.
Vyshak ChandraMartinos Center for Biomedical Imaging, Charlestown, USA.
Xiao DaMartinos Center for Biomedical Imaging, Charlestown, USA.
Yangming OuMartinos Center for Biomedical Imaging, Charlestown, USA.
Kyrre E EmblemMartinos Center for Biomedical Imaging, Charlestown, USA.
Alona MuzikanskyStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Yawkey 9E, 55 Fruit Street, Boston, MA, 02114, USA.
Xuezhu CaiMartinos Center for Biomedical Imaging, Charlestown, USA.
Linda DouwMartinos Center for Biomedical Imaging, Charlestown, USA.
John G EvansMartinos Center for Biomedical Imaging, Charlestown, USA.
Jorg DietrichStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Yawkey 9E, 55 Fruit Street, Boston, MA, 02114, USA.
Andrew S ChiLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA.
Patrick Y WenDana-Farber Cancer Institute, Boston, USA.
Stephen StufflebeamMartinos Center for Biomedical Imaging, Charlestown, USA.
Bruce RosenMartinos Center for Biomedical Imaging, Charlestown, USA.
Dan G DudaStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Yawkey 9E, 55 Fruit Street, Boston, MA, 02114, USA.
Rakesh K JainStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Yawkey 9E, 55 Fruit Street, Boston, MA, 02114, USA.
Tracy T BatchelorStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Yawkey 9E, 55 Fruit Street, Boston, MA, 02114, USA.
Elizabeth R GerstnerStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Yawkey 9E, 55 Fruit Street, Boston, MA, 02114, USA. egerstner@partners.org.
Athinoula A. Martinos Center for Biomedical Imaging · USCenter for Neuro-Oncology · USMassachusetts General Hospital · USDana-Farber Cancer Institute · USNYU Langone Health · US

Funding

Vascular Normalization: Rolse of Perivascular CellsP01CA080124 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2000 to 2016
$35.0M
ULTRAHIGH FIELD TECHNOLOGY FOR FUNCTIONAL IMAGINGP41RR014075 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 1999 to 2011
$16.4M
Quantitative Image Informatics for Cancer Research (QIICR)U24CA180918 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEDOROV, ANDRIY, KIKINIS, RON · 2013 to 2017
$4.0M
Quantitative MRI of Glioblastoma ResponseU01CA154601 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KALPATHY-CRAMER, JAYASHREE · 2011 to 2016
$3.4M
SILICON GRAPHICS PRISM EXTREME 128P/1TBS10RR023043 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI SORENSEN, ALMA GREGORY · 2006 to 2006
$1.5M
NCI NIH HHS P01 CA080124NCI NIH HHS U01 CA154601NCI NIH HHS U24 CA180918NCRR NIH HHS P41 RR014075NCRR NIH HHS S10 RR023043
6 · The paper itself

Abstract

Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24-72 h of treatment initiation, and monthly thereafter. Dynamic contrast enhanced MRI, dynamic susceptibility contrast MRI, and vessel architecture imaging were used to assess vascular effects. Resting state MRI was used to assess brain connectivity. Best RANO criteria responses were: 1 complete response, 1 partial response, 4 stable diseases, and 4 progressive disease (PD). Two patients were taken off study for toxicity and 8 patients were taken off study for PD. Median progression-free survival was 2.3 months and median overall survival was 8.1 months. Baseline abnormal tumor vascular permeability, blood flow, tissue oxygenation and plasma sVEGFR2 significantly decreased and plasma PlGF and VEGF increased after treatment, suggesting an anti-angiogenic effect of tivozanib. However, there were no clear structural changes in vasculature as vessel caliber and enhancing tumor volume did not significantly change. Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies.

Indexed as

Administration, OralAgedAntineoplastic AgentsBiomarkers, TumorBrain NeoplasmsFemaleGlioblastomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeovascularization, PathologicPhenylurea CompoundsQuinolinesReceptors, Vascular Endothelial Growth FactorSurvival AnalysisAntineoplastic AgentsBiomarkers, TumorPhenylurea CompoundsQuinolinesReceptors, Vascular Endothelial Growth FactortivozanibAnti-angiogenesisGlioblastomaMRIOverall survivalProgression-free survivalTivozanib

Identifiers

PMID27853960
PMCPMC7672995
OpenAlexW2554142171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.